Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Study finds DHA supplementation does not reduce risk of AD

Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.

3 Nov 2010

Medicare Roundup: Courts widen coverage of skilled care; experts give enrollment advice

Two federal courts have ruled that the Obama administration is using overly strict standards to determine whether older Americans are entitled to Medicare coverage of skilled nursing home care and home health care.

3 Nov 2010

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

Ligand Pharmaceuticals Incorporated today announced it has been awarded $1,955,834 in immediately available funds from the U.S. government under HR: 3590 - Patient Protection and Affordable Care Act. The award comprises separate payments of approximately $245,000 for each of eight drug development programs at Ligand.

2 Nov 2010

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).

2 Nov 2010

ArcticDx develops test to determine inherited risk for AMD

Established in 2007 and based in Toronto, ArcticDx has developed a test, Macula Risk-, the first of its kind and specifically designed to determine one's inherited risk for age-related macular degeneration (AMD), the most common form of acquired blindness in the developed world, affecting over 10% of individuals. ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.

2 Nov 2010

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

As the champagne corks are popping this New Year's Eve, the first American Baby Boomers will turn age 65. Members of the demographic bulge that transformed American politics and culture are expected to usher in yet another momentous change a huge increase in the number of Alzheimer's disease patients.

1 Nov 2010

2010 Mid-Atlantic Bio a great kick-off for hosting 2011 BIO International Convention

The 2010 Mid-Atlantic Bio today completed another successful conference hosting 728 registrants from 22 states and 4 countries, with more than 400 companies and 50 qualified investors participating. Dedicated to promoting the biotechnology industry in the Mid-Atlantic region, the conference is hosted collectively by the region's most influential bioscience and investor associations, the Mid-Atlantic Venture Association (MAVA), the Tech Council of Maryland/MdBio (MdBio) and the Virginia Biotechnology Association (VaBIO).

30 Oct 2010

FDA approves NUEDEXTA capsules for pseudobulbar affect

AVANIR Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.

30 Oct 2010

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it has created the Interlaken Leadership Awards. This global awards program will provide monetary grants to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders.

29 Oct 2010

EUCOMMTOOLS partners to receive 12 million euros research funding from European Commission

The findings will contribute to a better understanding of the pathogenesis of widespread diseases such as Alzheimer's, depression, diabetes, chronic lung diseases or cancer. Over the next five years, the eight EUCOMMTOOLS partners, coordinated by Professor Wolfgang Wurst of Helmholtz Zentrum M-nchen, will receive research funding amounting to approximately 12 million euros from the European Commission.

29 Oct 2010

Mary Ann Liebert launches Brain Connectivity journal

Mary Ann Liebert, Inc. announces the release of a new peer-reviewed journal in an expanding area of systems neuroscience, Brain Connectivity. This timely new journal is positioned to become the premier source of cutting-edge basic and clinical neuroscience research aimed at better understanding of structural and functional connections in the brain and how these connections are altered by neurological disorders.

29 Oct 2010

DiaGenic third quarter income increases from NOK -9.3 million to NOK -9.6 million

DiaGenic: The interim report for the third quarter 2010 was approved by the Board of Directors on 28 October 2010.

29 Oct 2010

ACADIA and BLS enter agreement to conclude pimavanserin collaboration

ACADIA Pharmaceuticals Inc. today announced that it has entered into an agreement with Biovail Laboratories International SRL ("BLS"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., pursuant to which ACADIA and BLS have agreed to conclude their previously established collaboration to develop and commercialize pimavanserin in the United States and Canada.

29 Oct 2010

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

Douglas C. Wallace, Ph.D., a pioneer and internationally prominent scientist in the field of human mitochondrial genetics, has joined The Children's Hospital of Philadelphia to continue his investigations into the role of mitochondrial energy in health and disease.

29 Oct 2010

ResMed third quarter revenue increases 17% to $282.0 million

ResMed Inc. today announced record revenue and income for the quarter ended September 30, 2010. Revenue for the quarter ended September 30, 2010 was $282.0 million, a 14% increase (a 17% increase on a constant currency basis) over the quarter ended September 30, 2009.

From ResMed Corp 29 Oct 2010

Common psychiatric drugs could slow dementia

Researchers say commonly used psychiatric drugs could be effective in slowing the progression of certain types of dementia. Dr John Kwok and colleagues from Neuroscience Research Australia have discovered a mutant gene that causes abnormal proteins build up in the brains of people with frontotemporal dementia, a disease that affects people in their 50s and 60s.

28 Oct 2010

World's largest research initiative to mutate all mouse genes

The world's largest research initiative to mutate all mouse genes is now able to reach the summit because the ambitious EUCOMMTOOLS project started on October 1, 2010. This project is being coordinated by Helmholtz Zentrum München and will finalize the groundwork for the analysis of all mouse gene functions. The findings will contribute to a better understanding of the pathogenesis of widespread diseases such as Alzheimer's, depression, diabetes, chronic lung diseases or cancer.

28 Oct 2010

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained an initial draft report of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON (OX1).

27 Oct 2010

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Elan Corporation, plc today reported its third quarter and first nine months 2010 financial results.

27 Oct 2010

Older adults with severe sepsis at higher risk for cognitive impairment

Older adults who survive severe sepsis are at higher risk for long-term cognitive impairment and physical limitations than those hospitalized for other reasons, according to researchers from the University of Michigan Health System.

27 Oct 2010

Alzheimer's Disease News and Research

Further Reading

Study finds DHA supplementation does not reduce risk of AD

Medicare Roundup: Courts widen coverage of skilled care; experts give enrollment advice

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

GSK's Revolade receives Japanese approval for treatment of chronic ITP

ArcticDx develops test to determine inherited risk for AMD

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

2010 Mid-Atlantic Bio a great kick-off for hosting 2011 BIO International Convention

FDA approves NUEDEXTA capsules for pseudobulbar affect

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

EUCOMMTOOLS partners to receive 12 million euros research funding from European Commission

Mary Ann Liebert launches Brain Connectivity journal

DiaGenic third quarter income increases from NOK -9.3 million to NOK -9.6 million

ACADIA and BLS enter agreement to conclude pimavanserin collaboration

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

ResMed third quarter revenue increases 17% to $282.0 million

Common psychiatric drugs could slow dementia

World's largest research initiative to mutate all mouse genes

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Older adults with severe sepsis at higher risk for cognitive impairment

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News